CCR9


Also found in: Medical.
AcronymDefinition
CCR9C-C Chemokine Receptor 9 (gene)
References in periodicals archive ?
Decision Resources surveyed EU5 gastroenterologists on three drugs in development for CD--Millennium's cell adhesion molecule (CAM) inhibitor vedolizumab, Centocor Ortho Biotech/Janssen-Cilag's interleukin (IL)-12/IL-23 inhibitor Stelara, and ChemoCentryx/GlaxoSmithKline's CCR9 chemokine receptor antagonist Traficet-EN (CCX-282B).
1, 2008, issue of Clinical Cancer Research, also suggests that merging of the protein, called CCR9, with the CCL25 protein, which is known to play a role in the development of disease-fighting white blood cells, may help to explain the high incidence of melanoma metastasis to the lower bowel.
Results of the study showed CCR9 in 88 of 102 metastatic melanomas from the small intestine; in contrast, none of the 96 melanomas from other metastatic organ sites showed the CCR9 protein.
ChemoCentryx's lead compound, Traficet-EN[R], a specific CCR9 antagonist, is currently in a multinational clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease.
is presenting clinical and preclinical data from studies of the company's drug candidate Traficet-EN[R] (CCX282-B) a first-in-class, orally active, anti-inflammatory agent that targets the chemokine receptor known as CCR9, at the 2006 Crohn's and Colitis Foundation of America's (CCFA) National Research and Clinical Conference/Fifth Annual Advances in the Inflammatory Bowel Diseases meeting being held December 1-3, 2006 in Miami, FL.
Eastern Standard Time in a presentation entitled "Traficet-EN (CCX282), an Orally Active Inhibitor of Chemokine Receptor CCR9 for Treatment of Crohn's Disease.
Traficet-EN[R] is a first-in-class, orally active, anti-inflammatory agent that targets the chemokine receptor known as CCR9.
ChemoCentryx's lead compound, Traficet-EN(R), a specific CCR9 antagonist is currently in a multinational clinical trial (PROTECT-1) of greater than 400 patients with moderate-to-severe Crohn's disease.
The agreement encompasses Traficet-EN, a specific CCR9 antagonist currently in a multinational clinical trial (PROTECT-1) of greater than 400 patients with IBD, as well as three ongoing pre-agreed preclinical research programs involving named but undisclosed chemokine and chemoattractant receptor targets.
Traficet-EN is a highly potent and selective inhibitor of the CCR9 chemokine receptor, which is specifically expressed on inflammatory cells homing to the digestive tract.
Traficet-EN is a novel, orally bioavailable, anti-inflammatory agent that targets the chemokine receptor known as CCR9.